| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4138622 | Seminars in Diagnostic Pathology | 2008 | 12 Pages |
Abstract
The article reviews the main molecular pathology alterations of endometrial and ovarian carcinomas and melanoma. Several promising drugs targeting the genes most frequently altered in these tumors are under consideration. The most promising signaling pathways to be targeted for therapies in these tumors are the tyrosine kinase receptor (EGFR, HER2, c-KIT), the RAS/B-RAF/MAPK, the PI3K–mTOR, and apoptosis signaling pathways.
Related Topics
Health Sciences
Medicine and Dentistry
Pathology and Medical Technology
Authors
Eugenia Ortega, Rosa M. Marti, Andree Yeramian, Anabel Sorolla, Xavier Dolcet, David Llobet, Leandro Abal, Maria Santacana, Judit Pallares, Antonio Llombart–Cussac, Xavier Matias–Guiu,